Cargando…
New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir
The combination therapy of ledipasvir/sofosbuvir was approved by the Food and Drug Administration in 2014 for the treatment of chronic hepatitis C. Although hyperglycemia is not well known to occur with its use, we present 2 cases of new-onset diabetes mellitus and a review of the literature suggest...
Autores principales: | Premji, Resmi, Roopnarinesingh, Nira, Qazi, Nazia, Nylen, Eric S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710113/ https://www.ncbi.nlm.nih.gov/pubmed/26788529 http://dx.doi.org/10.1177/2324709615623300 |
Ejemplares similares
-
Cerebral Malaria: An Unusual Cause of Central Diabetes Insipidus
por: Premji, Resmi, et al.
Publicado: (2016) -
Palisaded neutrophilic and granulomatous dermatitis associated with ledipasvir/sofosbuvir
por: Shenk, Mary Elizabeth Reed, et al.
Publicado: (2018) -
Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy
por: Janjua, Naveed Z., et al.
Publicado: (2019) -
Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2017) -
Real‐world safety and efficacy of sofosbuvir and ledipasvir for elderly patients
por: Tamai, Hideyuki, et al.
Publicado: (2018)